Targets › IL12B
9 programs from 8 companies in 158 trials: 49 Phase 2, 43 Phase 4, 42 Phase 3, 24 Phase 1; Immunology, Other, Gastroenterology; next expected readout Dec 2026.
Cytokine that can act as a growth factor for activated T and NK cells, enhance the lytic activity of NK/lymphokine-activated killer cells, and stimulate the production of IFN-gamma by resting PBMC..; FUNCTION: Associates with IL23A to form the IL-23 interleukin, a heterodimeric cytokine which functions in innate and adaptive immunity. IL-23 may constitute with IL-17 an acute response to infection in peripheral…. (UniProt, P29460)
Open in Phaseline: the race on IL12B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of California, San Francisco | Intravenous TXA Interleukin-23 inhibitor | ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4 | Phase 4 | Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke … | Dec 2026 |
| University of Calgary | CBD 100 mg OD Interleukin-23 inhibitor | CNR1, PLAT, IL12B, IL23A, ADRB2, HTR2A, NR3C1, TNF, PTGS2, PTGS1 | Phase 4 | Copd; Ehlers-Danlos Syndrome; Crohn Disease; Vasovagal Syncope … | Dec 2026 |
| Johnson & Johnson (Janssen) | Guselkumab (CNTO1959) Interleukin-23 inhibitor | IL12B, IL23A | Phase 4 | Arthritis, Psoriatic; Psoriasis; Colitis, Ulcerative; Crohn's Disease … | Dec 2026 |
| Eli Lilly | Mirikizumab (LY3074828) Interleukin-23 inhibitor | IL12B, IL23A | Phase 4 | Lactation; Crohn's Disease; Ulcerative Colitis; Colitis, Ulcerative … | Feb 2027 |
| AbbVie | Risankizumab Interleukin-23 inhibitor | IL12B, IL23A | Phase 3 | Psoriatic Arthritis; Crohn's Disease; Ulcerative Colitis; Crohn's Disease (CD) … | Jan 2027 |
| Sun Pharmaceutical Industries | Tildrakizumab Interleukin-23 inhibitor | IL12B, IL23A | Phase 3 | Active Psoriatic Arthritis; Moderate to Severe Genital Psoriasis; Psoriatic Arthritis; Moderate-to-severe Chronic Plaque Psoriasis | Feb 2027 |
| Johnson & Johnson (Janssen) | Ustekinumab Interleukin-12 inhibitor; Interleukin-23 inhibitor | IL12B, IL12A, IL23A | Phase 3 | Crohn Disease; Psoriasis; Crohn Disease (CD); Type 1 Diabetes Mellitus … | Sep 2027 |
| University Health Network, Toronto | ICG dye Interleukin-12 produced by genetically modified AML cells; immune stimulatory cytokine | IL12A, IL12B | Phase 2 | All Solid Tumors; Surgery Site Fistula; Acute Myeloid Leukemia; Melanoma (Skin) | Dec 2026 |
| Philogen | IL12-L19L19 Antibody-cytokine fusion protein; IL-12 fused to L19 antibody targeting fibronectin | IL12A, IL12B, FN1 | Phase 1 | Advanced Solid Tumor | Dec 2026 |
Crohn's Disease (11) Ulcerative Colitis (9) Crohn Disease (9) Psoriasis (8) Psoriatic Arthritis (4) Colitis, Ulcerative (3) Crohn Disease (CD) (3) Psoriasis Vulgaris (3) Nicotine Dependence (3) Ulcerative Colitis (UC) (2) Pouchitis (2) Arthritis, Psoriatic (2)
antibody (5), small molecule (2), protein or peptide (1)
Johnson & Johnson (Janssen) (2) AbbVie (1) Eli Lilly (1) Sun Pharmaceutical Industries (1) University of California, San Francisco (1) University of Calgary (1) Philogen (1) University Health Network, Toronto (1)
IL23A (7) IL12A (3) ADRB2 (2) NR3C1 (2) HTR2A (2) AGTR1 (1) PDCD1 (1) MAP2K1 (1) MAP2K2 (1) MS4A1 (1) CHRM3 (1) CHRM2 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.